CHOSA Oncology AB approved for re-listing at Spotlight’s ordinary list
CHOSA Oncology AB (the ”Company” or ”CHOSA Oncology”) have received approval for re-listing on Spotlight’s ordinary list. Spotlight decided by December 5th 2022 that the Company was a subject to a new listing process. The reason for the new listing process was to ensure that the Company fulfills all the listing requirements after the Company entered into an agreement to acquire all shares in Chosa ApS (”Chosa ApS”) through reversed merger. The Company has received approval for re-listing and will be transferred to Spotlights ordinary list from today, May 3 rd 2023. The share has been traded on Spotlight’s observation list since May 30th 2022.
Chosa ApS is a Danish biotechnology company founded in April 2022 and by in-licensing has worldwide rights to LiPlaCis® and it’s Drug Response Predictor (“DRP®”) together referred to as iCIP™. The drug candidate LiPlaCis® utilizes a liposomal carrier of the anticancer agent (cisplatin) that effectively targets cancer cells. The drug seems to have a milder toxicity profile to comparable drugs. The DRP® technology identifies if a patient will benefit from treatment with LiPlaCis® or not. The DRP® produces a score on the likelihood of the patient benefiting from the drug based on the individual gene expression of the patient’s biopsy allowing the doctor to choose to give the drug to the 20 percent of patients with the highest likelihood of benefit.
In November 2022, CHOSA ApS received positive phase 2b data from clinical trial with iCIP™ in metastatic breast cancer, which indicated that LiPlaCis® treatment of the DRP®-selected patients significantly increased response rate and progression-free survival. CHOSA’s main objective for 2023 is to find a partner to co-finance the upcoming clinical trial.
Peter Buhl, CEO for CHOSA Oncology AB, comments
”I would like to take the opportunity to thank investors for supporting CHOSA in our goal in bringing effective and safe precision medicine to cancer patients with huge medical need. Now we can look forward in increasing values and business development activities finding partners for iCIP.”
Re-listing at Spotlight’s ordinary list
CHOSA Oncology’s share will be re-listed at Spotlight’s ordinary list from today, May 3rd 2023.
The company description will soon be available at www.spotlightstockmarket.com.
For more information, please contact:
Carl-Henrik Nordberg
Head of Listing, Spotlight Stock Market
+46 70 589 80 07